Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KTX-0200
- Development stage
- Preclinical
- Lead developer
- Kintai Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**KTX-0200** is an oral small molecule anti-obesity agent developed by Kintai Therapeutics. It demonstrated sustained **14% body weight reduction** in 12-week chronic diet-induced obesity mouse and rodent models, alongside improvements in glucose control and liver health markers. The agent regulates carbohydrate absorption and increases colonic exposure to key microbial metabolites that act on human cells, advancing into IND-enabling studies for obesity treatment.[1][2][3][7][9][13]
Beyond the preview
Go deeper on KTX-0200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KTX-0200.